Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)


This is a prospective, randomized study to evaluate the efficacy and safety of ORACEA® in the treatment of geographic atrophy due to dry age-related macular degeneration (AMD).

Full Title of Study: “A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 2020

Detailed Description

Eligible participants will complete a 6-month Observation Phase, followed by a 24-month Treatment Phase, followed by an End of Study Visit. Eligible participants will be randomized at Month 6 in a 1:1 ratio to either ORACEA (40 mg doxycycline) or placebo capsule to be taken once-daily for 24 months. Over the course of the 31-month study, a total of 9 clinic visits and 3 telephone calls are required.


  • Drug: ORACEA®
    • ORACEA® (40mg doxycycline) capsule daily for 24 months
  • Drug: Placebo
    • Placebo capsule daily for 24 months

Arms, Groups and Cohorts

  • Experimental: ORACEA®
    • 40mg doxycycline
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Rate of enlargement in area of geographic atrophy in the study eye during the treatment period.
    • Time Frame: Month 6 and Month 30

Secondary Measures

  • Change in Best Corrected Visual Acuity (BCVA)
    • Time Frame: Month 6 and Month 30

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female, age >/=55 years – Best corrected visual acuity of 20/20 – 20/400 in the study eye – Best corrected visual acuity of hand motion or better in the non-study eye – Clinical diagnosis of geographic atrophy secondary to non-exudative age-related macular degeneration in at least one eye (study eye) – Geographic atrophy lesions of ≥ 0.5 and ≤ 7.0 MPS disc areas Exclusion Criteria:

  • History of or active presence of choroidal neovascularization secondary to exudative age-related macular degeneration in the study eye – History of or active presence of choroidal neovascularization secondary to exudative age-related macular degeneration in the non-study eye requiring any treatment within 12 months prior to Day 0 or expected to require treatment for the duration of the study – Prior treatment for non-exudative age-related macular degeneration – Current or previous history of treatment of the study eye with any tetracycline derivative for any ocular condition. – History of vitreoretinal surgery, corneal transplant, or laser photocoagulation in the study eye – Any intraocular or periocular surgery within 90 days prior to Day 0 in the study eye. – History of any hypersensitivity to tetracycline components – Use of a tetracycline derivative therapy for a concurrent systemic or ocular disorder within 90 days of Day 0 – History of sensitivity to the sun

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Paul Yates, MD, PhD
  • Collaborator
    • MEDARVA Foundation
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Paul Yates, MD, PhD, Associate Professor of Ophthalmology – University of Virginia
  • Overall Official(s)
    • Paul A Yates, MD, PhD, Principal Investigator, University of Virginia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.